Novel Drugs Recognized as a 'Pivotal Moment' in Combating Antibiotic-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.
A Global Health Concern
Gonorrhoea infections are increasing globally, with figures suggesting in excess of 82 million instances annually. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.
“The clearance of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”
Public health authorities are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.
Recent Therapies Secure Clearance
One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that targeted use of this new drug will help slow the development of resistance.
Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.
A Unique Approach to Creation
Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.
“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”
Research Study Data and Global Access
Based on findings released by a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The study involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.
Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.
Doctors directly involved have shared hope. Access to a easy-to-administer therapy like this is hailed as a "game-changer" for managing the epidemic. This is considered essential to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.
